BIOAGE LABS INC (BIOA)

Company Profile

BIOAGE Labs Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Richmond California, California. The company went IPO on 2024-09-26. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. The company has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. The company is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.

Company Info

BIOAGE LABS INC

1445A South 50Th Street

Richmond California CALIFORNIA H3B 4W8

P: 15108061445

CEO: Fabrice Orecchioni

Employees: 58

Website: https://bioagelabs.com